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This special issue is aimed at providing innovative scien-
tific data and discussing in-depth results and findings so
far available to further clarify some pivotal scientific topics
in the field of inositol(s). The authors focused their
attention on three essential molecules belonging to this
primordial group of ubiquitary chemical compounds:
myoinositol and D-chiroinositol, two stereoisomeric forms
of inositol(s), and inositol hexakisphosphate, a metabolite
of myoinositol. These molecules are involved in many
physiological functions and can be used for numerous
therapeutic aims, in some cases exploiting their feature
to exist in different enantiomeric forms, each one with
specific tasks. Plenty of experimental and clinical data have
shown that myoinositol alone, or (depending on the
therapeutic aim) in association with D-chiroinositol in a
physiologic ratio (40 : 1) between the two molecules, plays
a pivotal role in treating several pathologies such as PCOS,
metabolic syndrome, gestational diabetes, thyroid disor-
ders, and infertility. Furthermore, myoinositol allows also
improving substantially the outcomes of assisted reproduc-
tion technology (ART). Finally, myoinositol and inositol
hexakisphosphate have demonstrated very promising anti-
cancer activities as shown by numerous studies.
Although an increasing number of researches and inves-
tigations were realized on inositol(s) physiological properties
as well as on the pathological conditions caused by their
imbalance, a few points had to be reaffirmed and examined
in-depth. The effort by the authors to address these issues
was stimulated by the necessity to clear up a couple of
improper ideas about the physiological functions carried
out by myoinositol and D-chiroinositol. As a matter of fact,
we may say that so far, not enough attention has been paid
to this issue, at least in some cases. Despite the fact that it
was well shown that such molecules play basic but very differ-
ent roles in regulating various metabolic pathways and
hormonal signaling, a fewproposals of therapeutic application
reveal to be still not appropriately focused. It is essential to
highlight that myoinositol, the most represented and impor-
tant stereoisomeric formof inositol, stands out for its key roles
as leading molecule in some physiological areas, whereas dif-
ferent integrative functions are carried out byD-chiroinositol,
synthetized from myoinositol under the enzymatic control of
an epimerase. To get straight to the point, whereas the activa-
tion of glucose transporters and glucose utilization take place
under the regulation of myoinositol, glycogen synthesis is
mainly controlled by D-chiroinositol. On the other hand, in
the ovary, myoinositol regulates glucose uptake and FSH
signaling, while D-chiroinositol modulates insulin-induced
androgen synthesis [1, 2]. In physiological conditions, the
intracellular pool of inositol(s) in human ovaries and testis
contains 99% of myoinositol whereas the remaining part is
D-chiroinositol [2, 3]. It means that myoinositol is essential
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qualitatively and quantitatively for the functioning of the
reproductive system.
It was discovered that an imbalance between myoinositol
and D-chiroinositol concentrations occurs in the ovary of
PCOS women, with a myoinositol deficiency, which might
impair the FSH signaling [2, 3]. In these conditions, glucose
uptake and metabolism in oocytes and follicular cells are
negatively affected, thereby compromising oocyte quality
that depends on the availability of adequate amounts of myo-
inositol [2, 3]. The improvement of ovarian function, as well
as hormonal and metabolic parameters, was demonstrated
after myoinositol treatment in PCOS women [2, 3]. On the
other hand, high doses of D-chiroinositol alone, adminis-
tered to PCOS subjects, were found significantly detrimental
for oocytes and therefore for fertility [2, 3]. Finally, it is not to
be forgotten that myoinositol is a well-established safe mole-
cule [4]. By now, it is possible to outline a comprehensive
framework and bring about the best treatment for PCOS in
keeping with the above cited findings, specifying some mile-
stones useful for the therapeutic application. Many articles of
the special issue contributed to further shed light on this
topic and strengthen several points with original studies
and insightful reviews of up-to-date scientific literature. In
our systematic review (V. Unfer et al.), we analysed recent
randomized clinical trials of inositol(s) in PCOS, in particular
myo- and D-chiroinositol, aiming at better elucidating their
physiological involvement in PCOS and potential therapeutic
use, alone and in conjunction with assisted reproductive
technologies, in the clinical treatment of women with PCOS.
Other articles reported the results of a study on the putative
role due to D-chiroinositol and its messenger in insulin resis-
tance in women with PCOS independent of obesity (K. I.
Cheang et al.) and an in-depth investigation on the possible
involvement of inositol messengers in pre-eclampsia (S.
Kunjara et al.). Other contributions were focused on PCOS
therapy (and in a lesser extent on gestational diabetes and
metabolic syndrome therapy), regarding the improvement
of the metabolic profile and also the restoration of patients’
fertility (A. S. Laganà et al., G. Muscogiuri et al.). On the same
topic besides the cited reviews, various clinical studies are
presented and carried out in adults (E. Benelli et al.,
A. C. Ozay et al., and S. Salehpour et al.) and teenagers
(L. Pkhaladze et al.). Myoinositol was proven to be effi-
cacious in increasing significantly the overall rate of live
births in female mice (N. Kuşcu et al.), and in treating
infertility in men, with or without metabolic syndrome
(two studies by M. Montanino et al., M. Palmieri
et al.), and in women affected or not by PCOS (D. Garg
et al., B. Lesoine et al., P.-A. Regidor and A. E. Schindler,
G. Simi et al., S. G. Vitale et al., andA.Wdoviak).Myoinositol,
in association with folic acid, administered during preg-
nancy, was found to be very efficacious in warding off the
occurrence of neural tube defects in infants (P. Cavalli
and E. Ronda). Furthermore, other studies and reviews inves-
tigated the promising effects of myoinositol and selenium
in the treatment of autoimmune thyroiditis (M. Nordio
and S. Basciani), myoinositol plus D-chiroinositol, at the
physiological ratio (40 : 1), for the therapy of type 2 diabetes
(B. Pintaudi et al.) and for improving insulin resistance in
obese male children (M. Mancini et al.). Also, myoinositol
and its metabolite, inositol hexakisphosphate, deserve to be
carefully taken into consideration. Both these molecules exert
a wide range of critical activities in physiological and patho-
logical settings. Deregulated inositol(s) metabolism was
observed in a number of diseases, including cancer, where
they modulate different critical pathways. Inositol hexaki-
sphosphate was found to inhibit growth and invasiveness of
several cancer types, whereas both inositol hexakisphosphate
and myoinositol exert substantial chemopreventive effects
in vitro and in vivo. Of note, myoinositol is able to signifi-
cantly synergize with inositol hexakisphosphate in inducing
cancer inhibition. Moreover, they are provided with antioxi-
dant activity, moderate inmyoinositol, and very high in inosi-
tol hexakisphosphate. The second one acts as a chelator of
harmful trace elements, such as iron, uranium, nickel, copper,
and other potentially toxic elements, often involved in tumor
onset. In addition to that, these inositols modulate processes
such as mRNA transcription, chromatin remodeling, cyto-
skeleton configuration, and p53 activity, to name a few.
Thereby, inositol hexakisphosphate or myoinositol alone, or
in synergy, can be excellent therapeutic agents that protect
from cancer and other threats to human health (M. Bizzarri
et al., R. Lauretta et al.).
We outlined the framework in which our special issue is
placed, providing a guiding thread for reading the various
contributions according to the topics covered by the authors.
These articles convey a clear picture and can elicit new
insights in researchers and readers concerning the studies
on inositol(s).
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